PCRX Pacira BioSciences Inc

Price (delayed)

$27.81

Market cap

$1.29B

P/E Ratio

198.64

Dividend/share

N/A

EPS

$0.14

Enterprise value

$1.78B

Pacira BioSciences, Inc.is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. The company's long-acting local ...

Highlights

Pacira BioSciences's debt has decreased by 28% YoY and by 4.9% from the previous quarter

The company's quick ratio rose by 21% QoQ and by 11% YoY

The company's gross margin fell by 4% YoY but it rose by 2.2% QoQ

Pacira BioSciences's EPS has shrunk by 69% YoY

The company's net income has shrunk by 67% YoY

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Website: http://www.pacira.com

Peers: DRRX HRTX CARA CPIX

Key stats

What are the main financial stats of PCRX

Market

Shares outstanding

46.44M

Market cap

$1.29B

Enterprise value

$1.78B

Valuations

Price to earnings (P/E)

198.64

Price to book (P/B)

1.55

Price to sales (P/S)

1.94

EV/EBIT

47.07

EV/EBITDA

14.22

EV/Sales

2.68

Earnings

Revenue

$665.69M

EBIT

$37.87M

EBITDA

$125.37M

Free cash flow

$130.25M

Per share

EPS

$0.14

Free cash flow per share

$2.81

Book value per share

$17.91

Revenue per share

$14.34

TBVPS

$18.82

Balance sheet

Total assets

$1.53B

Total liabilities

$702.91M

Debt

$590.3M

Equity

$831.55M

Working capital

$353.59M

Liquidity

Debt to equity

0.71

Current ratio

4.78

Quick ratio

3.55

Net debt/EBITDA

3.92

Margins

EBITDA margin

18.8%

Gross margin

70.1%

Net margin

Operating margin

6.7%

Efficiency

Return on assets

0.4%

Return on equity

0.9%

Return on invested capital

2.8%

Return on capital employed

2.6%

Return on sales

5.7%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

PCRX stock price

How has the Pacira BioSciences stock price performed over time

Intraday

1.94%

1 week

3.34%

1 month

-1.77%

1 year

-41.12%

YTD

-27.97%

QTD

-9.35%

Financial performance

How have Pacira BioSciences's revenue and profit performed over time

Revenue

$665.69M

Gross profit

$466.8M

Operating income

$44.61M

Net income

$6.98M

Gross margin

70.1%

Net margin

Pacira BioSciences's net margin has plunged by 69% YoY

The company's net income has shrunk by 67% YoY

PCRX's operating margin is down by 41% YoY and by 7% QoQ

The company's operating income fell by 40% YoY and by 7% QoQ

Growth

What is Pacira BioSciences's growth rate over time

Valuation

What is Pacira BioSciences stock price valuation

PCRX P/E details

P/E

198.64

P/B

1.55

P/S

1.94

EV/EBIT

47.07

EV/EBITDA

14.22

EV/Sales

2.68

Pacira BioSciences's EPS has shrunk by 69% YoY

PCRX's P/B is 61% below its 5-year quarterly average of 4.0 and 30% below its last 4 quarters average of 2.2

The equity has increased by 8% year-on-year and by 2.9% since the previous quarter

The price to sales (P/S) is 57% lower than the 5-year quarterly average of 4.5 and 25% lower than the last 4 quarters average of 2.6

Efficiency

How efficient is Pacira BioSciences business performance

PCRX's ROE has dropped by 68% year-on-year

Pacira BioSciences's ROA has plunged by 64% YoY

Pacira BioSciences's return on sales has decreased by 42% YoY but it has increased by 30% QoQ

Pacira BioSciences's ROIC has increased by 33% from the previous quarter but it has decreased by 33% YoY

Dividends

What is PCRX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for PCRX.

Financial health

How did Pacira BioSciences financials performed over time

The total assets is 118% greater than the total liabilities

PCRX's total liabilities is down by 27% YoY and by 4.3% QoQ

The current ratio has grown by 21% from the previous quarter and by 18% YoY

Pacira BioSciences's debt is 29% less than its equity

Pacira BioSciences's debt to equity has decreased by 34% YoY and by 8% from the previous quarter

Pacira BioSciences's debt has decreased by 28% YoY and by 4.9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.